RFK Jr. pulls $500 million in funding for vaccine development
Robert F. Kennedy Jr. announced in a statement Tuesday that 22 projects, totaling $500 million, to develop vaccines using mRNA technology will be halted.
Kennedy's decision to terminate the projects is the latest in a string of decisions that have put the longtime vaccine critic's doubts about shots into full effect at the nation's health department. Kennedy has pulled back recommendations around the COVID-19 shots, fired the panel that makes vaccine recommendations, and refused to offer a vigorous endorsement of vaccinations as a measles outbreak worsened.
The health secretary criticized mRNA vaccines in a video on his social media accounts, explaining the decision to cancel projects being led by the nation's leading pharmaceutical companies, including Pfizer and Moderna, that offer protection against viruses such as the flu, COVID-19 and H5N1.
'To replace the troubled mRNA programs, we're prioritizing the development of safer, broader vaccine strategies, like whole-virus vaccines and novel platforms that don't collapse when viruses mutate,' Kennedy said in the video.
Infectious disease experts say the mRNA technology used in vaccines is safe, and they credit its development during the first Trump administration with slowing the 2020 coronavirus pandemic. Future pandemics, they warned, will be harder to stop without the help of mRNA.
'I don't think I've seen a more dangerous decision in public health in my 50 years in the business,' said Mike Osterholm, a University of Minnesota expert on infectious diseases and pandemic preparations.
He noted mRNA technology offers potential advantages of rapid production, crucial in the event of a new pandemic that requires a new vaccine.
The shelving of the mRNA projects is short-sighted as concerns about a bird flu pandemic continue to loom, said Dr. Paul Offit, a vaccine expert at Children's Hospital of Philadelphia.
'It's certainly saved millions of lives,' Offit said of the existing mRNA vaccines.
Scientists are using mRNA for more than infectious disease vaccines, with researchers around the world exploring its use for cancer immunotherapies. At the White House earlier this year, billionaire tech entrepreneur Larry Ellison praised mRNA for its potential to treat cancer.
Traditionally, vaccines have required growing pieces of viruses, often in chicken eggs or giant vats of cells, then purifying that material. The mRNA approach starts with a snippet of genetic code that carries instructions for making proteins. Scientists pick the protein to target, inject that blueprint and the body makes just enough to trigger immune protection — producing its own vaccine dose.
In a statement Tuesday, HHS said 'other uses of mRNA technology within the department are not impacted by this announcement.'
The mRNA technology is used in approved COVID-19 and RSV shots, but has not yet been approved for a flu shot. Moderna, which was studying a combination COVID-19 and flu mRNA shot, had said it believed mRNA could speed up production of flu shots compared with traditional vaccines.
The abandoned mRNA projects signal a 'shift in vaccine development priorities,' the health department said in its statement, adding that it will start 'investing in better solutions.'
'Let me be absolutely clear, HHS supports safe, effective vaccines for every American who wants them,' Kennedy said in the statement.
Speaking hours later Tuesday at a news conference in Anchorage, Alaska, alongside the state's two Republican U.S. senators, Kennedy said work is underway on an alternative.
He said a 'universal vaccine' that mimics 'natural immunity' is the administration's focus.
'It could be effective — we believe it's going to be effective — against not only coronaviruses, but also flu,' he said.
Seitz writes for the Associated Press. AP writers Lauran Neergaard in Washington, Mike Stobbe in New York and Becky Bohrer in Juneau contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
11 minutes ago
- The Hill
ACA premiums set to spike
The proposed rates are preliminary and could change before being finalized in late summer. The analysis includes proposed rate changes from 312 insurers in all 50 states and DC. It's the largest rate change insurers have requested since 2018, the last time that policy uncertainty contributed to sharp premium increases. On average, ACA marketplace insurers are raising premiums by about 20 percent in 2026, KFF found. Insurers said they wanted higher premiums to cover rising health care costs, like hospitalizations and physician care, as well as prescription drug costs. Tariffs on imported goods could play a role in rising medical costs, but insurers said there was a lot of uncertainty around implementation, and not many insurers were citing tariffs as a reason for higher rates. But they are adding in higher increases due to changes being made by the Trump administration and Republicans in Congress. For instance, the majority of insurers said they are taking into account the potential expiration of enhanced premium tax credits. Those subsidies, put in place during the COVID-19 pandemic, are set to expire at the end of the year, and there are few signs that Republicans are interested in tackling the issue at all. If Congress takes no action, premiums for subsidized enrollees are projected to increase by over 75 percent starting in January 2026, according to KFF. But some states are pushing back. Arkansas Gov. Sarah Huckabee Sanders (R) on Wednesday called on the state's insurance commissioner to disapprove the proposed increases from Centene and Blue Cross Blue Shield. The companies filed increases of up to 54 percent and 25.5 percent, respectively, she said. 'Arkansas' Insurance Commissioner is required to disapprove of proposed rate increases if they are excessive or discriminatory, and these are both,' Huckabee Sanders said in a statement. 'I'm calling on my Commissioner to follow the law, reject these insane rate increases, and protect Arkansans.'
The Hill
an hour ago
- The Hill
Huge cuts to mRNA research spark fears about future pandemics
Health Secretary Robert F. Kennedy Jr.'s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding will leave the United States unprepared for the next pandemic and other public health emergencies, public health experts warned. 'I've tried to be objective & non-alarmist in response to current HHS actions—but quite frankly this move is going to cost lives,' President Trump's former surgeon general Jerome Adams said in a post to X. 'mRNA technology has uses that go far beyond vaccines… and the vaccine they helped develop in record time is credited with saving millions.' The first COVID-19 mRNA vaccines from Pfizer and Moderna hit the market in 2021, just a year after the virus first appeared. Vaccines typically take years to develop, but the mRNA shots were developed in record time due to a massive influx of funding from the first Trump administration, dubbed Operation Warp Speed. The COVID shots proved safe and effective, and helped bring about an end to the pandemic. Experts say mRNA technology has the potential to revolutionize treatments for evolving pathogens, especially bird flu, because the platform can be easily modified. On Tuesday, Kennedy cancelled $500 million worth of contracts related to mRNA vaccine research being funded by the Biomedical Advanced Research and Development Authority. Instead, he said the agency will focus on platforms with 'stronger safety records.' Public health experts point out that reviews of the hundreds of millions, if not billions, of doses of mRNA shots administered worldwide have found very few adverse events. 'It's pretty clear that the administration, or at least the secretary, has a political vendetta not just against vaccines but against mRNA in general,' said Jeff Coller, a professor of RNA biology and therapeutics at Johns Hopkins University. Coller said the move will put the U.S. behind other nations in biomedical research and sends a 'clear message' to scientists and the industry that it is not wise to invest in mRNA technology because if they do, they will likely not receive funding or approval from the federal government. Jennifer Nuzzo, a professor of epidemiology and director of the Pandemic Center at Brown University School of Public Health, told The Hill that the cancellation is a threat to national security, as it opens the U.S. to future public health emergencies caused by biological warfare. 'One of the ways that we deter that from happening is to say the United States is absolutely committed to preparedness,' Nuzzo said. 'When we take them off the table and leave nothing in their place, we basically signal to our adversaries that we are no longer interested in defending ourselves.' In the long run, Nuzzo said, winding down research efforts on mRNA vaccine platforms will stifle medical innovation coming out of the U.S., including new treatments for diseases like cancer. 'It's troubling on a number of fronts,' she said. MRNA vaccines work by sending instructions to cells to make a specific type of protein found on the outer membrane of a virus. The body's immune system is then able to recognize that protein as something foreign and will create antibodies to fight it. That same general approach could be used to help potentially vaccinate someone against a particular cancer, according to Nuzzo. 'Cancers have a genetic signature,' she said. 'We don't know what's going to happen but there are some preliminary studies that suggest it could be a very promising way to treat cancers.' None of the canceled contracts directly deal with cancer research, but the move will likely cause a chilling effect among researchers that ultimately impacts cancer-related work, said Michael Osterholm, founding director of the Center for Infectious Disease Research and Policy and member of the Vaccine Integrity Project. 'I think you're going to see anyone who is willing to invest in mRNA technology, pulling back, if not completely, getting out of this business,' he said. 'This is terribly unfortunate, given that we have a number of other infectious diseases for which this vaccine platform was being explored in terms of taking on other infectious diseases and including some cancer vaccines.' Kennedy is deeply skeptical of vaccines in general, and mRNA vaccines in particular. In 2021, he falsely said the mRNA COVID-19 vaccine was the 'deadliest vaccine ever made.' Kennedy has also been facing pressure from fellow anti-vaccine activists for not doing enough to keep mRNA vaccines off the market. He was criticized earlier this year when the Food and Drug Administration approved Moderna's updated COVID-19 vaccine, even though the agency limited its use in children. In a video posted to X on Tuesday, Kennedy falsely claimed mRNA shots don't protect against respiratory viruses and don't work if a virus mutates. 'One mutation and the vaccine becomes ineffective,' Kennedy said. Following the announcement, public health experts urged Congress to restore funding towards mRNA vaccine research, with some calling it an 'assault' on federal vaccine policy. 'The HHS Secretary continues a mindless assault on sound federal vaccine policy,' said Robert Steinbrook, director of the Public Citizen Health Reseach Group. 'The mRNA vaccine platform was essential to rapid vaccine development and deployment during the COVIVD-19 pandemic and remains essential to preparing for future public health emergencies.' But the full extent of Kennedy's move isn't known. A Moderna spokesperson told The Hill that they were not aware of any new award cancellations since their contract to help develop an H5N1 bird flu vaccine was canceled in May. Gritstone Bio, another company on the HHS list of cancelled contracts, ceased operations earlier this year after the company filed for bankruptcy in 2024. A spokesperson for Tiba Bio said HHS's decision to terminate their BARDA contract 'comes as a surprise' since its contract was for a therapeutic, not a vaccine, and it does not use mRNA technology. Instead, it uses a method called RNA interference, which the FDA approved to treat some diseases in 2018.
Newsweek
2 hours ago
- Newsweek
Trump Brushes Off Major Success From First Term: 'Long Time Ago'
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. President Donald Trump on Wednesday brushed off what is widely considered to be among the biggest uncontested successes of his first term while reacting to Health and Human Services Secretary Robert F. Kennedy Jr.'s move to pull $500 million in funding for next-generation mRNA-based vaccines to tackle viruses like Covid, H5N1 and the flu. "You were the driving force behind Operation Warp Speed, these mRNA vaccines that are the gold standard," a reporter asked Trump during a White House event on Wednesday. Operation Warp Speed was a 2020 public-private partnership, initiated by the first Trump administration, aimed at accelerating the development and distribution of a COVID-19 vaccine. At the time, it was almost universally accepted that an effective vaccine for the coronavirus was at least 18 months to two years away. Trump's operation did it in less than a year. "Now, your health secretary is pulling back all the funding for research, he's saying that the risks outweigh the benefits, which puts him at odds with the entire medical community, and with you," the reporter continued. "What's going on?" "Research on what?" Trump asked. "Into mRNA vaccines," she clarified. "Well, we're going to look at that," the president replied. "We're talking about it and they're doing a very good job, and you know, that is a pass." Trump went on to briefly acknowledge the success of Operation Warp Speed before dismissing it. "Operation Warp Speed was, whether you're a Republican or Democrat, considered one of the most incredible things ever done in this country," the president said. "The efficiency, the way it was done, the distribution, everything about it has been amazing." Then he added: "But, you know, that was now a long time ago. And we're onto other things, but we are speaking about it. We have meetings about it ... we're looking for other answers to other problems, to other sicknesses and diseases and I think we're doing really well." This is a breaking news story. Updates to follow.
